SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Non-Small Cell Lung Cancer

About this trial

Lung cancer is a common cancer worldwide. Non small cell lung cancer (NSCLC) makes up a large proportion of all lung cancers. The most common course of treatment for patients with small volume NSCLC is surgery. That said, approximately one quarter of patients are not suitable for surgery. These patients are treated with radiation therapy. Most commonly this radiation therapy is delivered over 30-33 treatments. This study looks at delivering the same overall dose of radiation but in 8 treatments rather than 30-33 using a method called image guided stereotactic ablative radiation therapy (SABR). The study is aiming to determine the safety of delivering the radiation therapy in 8 treatments in terms of side effects experienced up to one year after treatment. All patients on this study will receive the same treatment. Patients will be monitored closely throughout their treatment and for another 5 years after the end of treatment. All patients will also be asked to fill in quality of life questionnaires at certain points during the study.

Patient Profile

Patients with medically inoperable, early stage, high-risk centrally located non small cell lung cancer.

Where’s this trial being run?

St Luke’s Radiation Oncology Network @ St James’s Hospital and St Luke’s Radiation Oncology Network @ St Luke’s Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Non-Small Cell Lung Cancer
Number: 18-33
Full Title:

SOURCE – LUNG:
Stereotactic Ablative Radiation Therapy Of Ultracentral Non-Small Cell Lung Cancer

Principal Investigator: Prof John Armstrong
Type: In-House
Sponsor:

Cancer Trials Ireland

Recruitment Started: Global: 22-Dec-2020
Ireland: 22-Dec-2020
Global Recruitment Target: 191
Ireland Recruitment Target: 191